Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic inhibition of receptor protein tyrosine phosphatase β/ζ reduces amyloid plaque load and modulates pleiotrophin-expressing glial cells, glial-plaque interactions and genes related to amyloid beta clearance.

Frontiers in pharmacology·2026
Same author

Correspondence on 'Safety and immunogenicity of the recombinant zoster vaccine in patients with rheumatoid arthritis using abatacept: a pilot multicentre, double-blind, randomised controlled trial' by Hawkins et al.

Annals of the rheumatic diseases·2026
Same author

Beyond DSM Categories: Criteria for Biologically Valid Disease Axes in Psychiatry.

Journal of clinical medicine·2026
Same author

Observed incidence is not biologic risk.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Pesticide Residues in Fruits: From Surveillance Data to Risk-Based Interpretation and Mitigation.

Molecules (Basel, Switzerland)·2026
Same author

Gucagon-like peptide-1 receptor agonists and pulmonary aspiration: stratify physiology, not prescriptions.

British journal of anaesthesia·2026

Related Experiment Video

Updated: May 20, 2026

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
09:07

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay

Published on: December 19, 2018

Towards β-selectivity in functional estrogen receptor antagonists.

Jose Juan Rodríguez1, Kamila Filipiak, Maciej Maslyk

  • 1Departamento de Química, Facultad de Farmacia, Universidad CEU San Pablo, 28668-Boadilla del Monte, Madrid, Spain.

Organic & Biomolecular Chemistry
|August 1, 2012
PubMed
Summary

Researchers developed novel ligands based on benzo[b]naphtho[1,2-d]furan and benzo[b]naphtho[1,2-d]thiophene frameworks. Two potent and selective estrogen receptor beta (ERβ) antagonists were identified, offering new tools for studying estrogen receptor functions.

More Related Videos

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Related Experiment Videos

Last Updated: May 20, 2026

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
09:07

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay

Published on: December 19, 2018

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Area of Science:

  • Medicinal Chemistry
  • Molecular Pharmacology
  • Drug Discovery

Background:

  • Estrogen receptors (ERs) play critical roles in various physiological processes.
  • Selective modulation of ERα and ERβ subtypes is crucial for targeted therapies.
  • Benzo[b]naphtho[1,2-d]furan and benzo[b]naphtho[1,2-d]thiophene scaffolds are explored for potential ER activity.

Purpose of the Study:

  • To synthesize and evaluate novel ligands based on benzo[b]naphtho[1,2-d]furan and benzo[b]naphtho[1,2-d]thiophene frameworks.
  • To investigate the structure-activity relationships and binding modes of these ligands with ERα and ERβ.
  • To identify selective ERβ antagonists for potential therapeutic applications and mechanistic studies.

Main Methods:

  • Synthesis of ligands incorporating different basic side chains (BSCs).
  • In vitro competitive binding assays to determine receptor affinity.
  • Cell-based luciferase reporter assays to assess functional antagonism.
  • Molecular docking techniques to model ligand-receptor interactions.

Main Results:

  • Introduction of BSCs generally decreased affinity for both ERα and ERβ.
  • Two compounds (9c and 9f) emerged as potent, low micromolar ERβ antagonists.
  • Compounds 9c and 9f showed no activity against ERα at the tested concentrations.
  • Molecular modeling provided insights into differential binding modes between ERα and ERβ.

Conclusions:

  • Novel benzo[b]naphtho[1,2-d]furan/thiophene derivatives were synthesized and characterized.
  • Selective ERβ antagonists (9c and 9f) were discovered with potential for elucidating ER subtype-specific roles.
  • The identified ligands offer a promising chemical platform for developing subtype-selective ER modulators.